In A Phase III Lipid Interim Analysis, ACAPODENE Treatment Lowered Cholesterol And Raised HDL In Prostate Cancer Patients On Androgen Deprivation

... GTx, Inc. (Nasdaq:GTXI), the Men's Health Biotech Company, announced today the results of alipid interim analysis of the pivotal Phase III ADT clinical trialevaluating oral, once daily ACAPODENE(R) (toremifene citrate) 80mg for thetreatment of the multiple serious side effects of androgen deprivationtherapy (ADT) in men with advanced prostate cancer. [click link for full article] ...